Abstract #0978

DMSO-Based Contrast as a Potential Intermediate Endpoint Biomarker of GBM Response to Therapy.

Teresa Delgado-Goi^1,2, Juana Martin-Sitjar^1,2, Rui V. Simes^1,2, Milena Acosta^1,2, Silvia Lope-Piedrafita^2,3, Carles Ars^1,2

¹Bioquimica i Biologia Molecular, Universitat Autnoma Barcelona, Cerdanyola del Valls, Barcelona, Spain; ²Centro de Investigacin Biomdica en Red en Bioingeniera, Biomateriales y Nanomedicina (CIBER-BBN), Cerdanyola del Valls, Barcelona, Spain; ³Servei de Ressonncia Magntica Nuclear, Universitat Autnoma de Barcelona, Cerdanyola del Valles, Barcelona, Spain

Dimethyl Sulfoxide (DMSO) is a common administration vehicle for some drugs, such as temozolomide (TMZ). DMSO has been reported to cross the blood-brain-barrier and to produce contrast, detected by 1H MRS/MRSI, between GL261 mouse glioblastoma (GBM) and nearby/peritumoral brain parenchyma. This work evaluates the effect of TMZ in mouse GBM progression, which can be monitored by T2w MRI as a transient volume growth arrest. MRSI-detection of differential DMSO accumulation in GL261 treated with respect to non-treated tumours provides a non-invasive biomarker of this response.